Piper Sandler Maintains Overweight on Xeris Biopharma Holdings, Lowers Price Target to $4-Report released on 9th Nov 2023
Portfolio Pulse from Benzinga Newsdesk
Piper Sandler analyst David Amsellem has maintained an Overweight rating on Xeris Biopharma Holdings (NASDAQ:XERS) but reduced the price target from $5 to $4. The report was released on November 9, 2023.
November 10, 2023 | 10:21 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Piper Sandler has maintained an Overweight rating on Xeris Biopharma Holdings but lowered the price target from $5 to $4.
While the maintenance of an Overweight rating suggests continued confidence in the company's prospects, the reduction in the price target could signal a tempered expectation for the stock's performance. This mixed signal may lead to a neutral short-term impact on the stock price as the market digests both the reaffirmation of the positive rating and the lower price target.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100